The 5 most recent market catalysts affecting $RAD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 75
Radiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma
Radiopharm Theranostics (RAD) has reported encouraging Phase 1 trial results for RAD301, a diagnostic imaging agent targeting αvβ6-integrin in pancreatic cancer. The positive safet…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Radiopharm Theranostics Says Data Safety And Monitoring Committee Recommends Advancing RAD202 To 180mCi Dose Level In Phase 1 HEAT Trial In HER2-Positive Advanced Solid Tumors
This news is a significant positive catalyst for Radiopharm Theranostics (RAD). The recommendation to advance RAD202 to a higher dose level in a Phase 1 trial implies that the Data…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 75
Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy
Radiopharm Theranostics announced a significant milestone by securing an End-of-Phase 2 meeting with the FDA for RAD101, scheduled for October 1, 2026. This meeting is crucial for …
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort Of RAD204; First RECIST-Confirmed Durable Partial Response At Current Highest Dose Level #3, With Patient Progression Free Beyond Seven Months
Radiopharm Theranostics announced updated clinical results for its drug candidate, RAD204, in a cancer trial. The key takeaway is the first RECIST-confirmed durable partial respons…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 75
Radiopharm Theranostics Announces Data From All Thirty Evaluable Patients In Its Phase 2B Trial Of RAD101 In Participants With Suspected Recurrence Of Brain Metastases After Radiotherapy; RAD101 PET Demonstrated 93% Concordance With MRI Across All Evaluable Lesions, Meeting The Primary Endpoint
Radiopharm Theranostics reported that its RAD101 PET diagnostic for brain metastases achieved 93% concordance with MRI in its Phase 2B trial, meeting the primary endpoint. This is …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.